In a nutshell This trial looked at the quality of life (QOL) of patients receiving PVd (pomalidomide, bortezomib, dexamethasone) for multiple myeloma which has returned after previous treatment. This study showed that adding pomalidomide (Pomalyst) to the Vd regimen (bortezomib, dexamethasone) did not decrease patients' QOL. Some background...
Read MoreQuality of life during treatment with PVd for multiple myeloma
